6533b832fe1ef96bd129ac74

RESEARCH PRODUCT

FEV1 Predicts Cardiac Status and Outcome in Chronic Heart Failure

Tommaso GoriGregor BuchAlexander SchuchPhilipp S. WildAndreas SchulzThomas MünzelMarc HeidornFelix MüllerSven-oliver TröbsKarl J. LacknerStefanie SteckJürgen H. ProchaskaIrene SchmidtmannSören Schwuchow-thonkeKonstantin Strauch

subject

Pulmonary and Respiratory MedicineCardiac function curvemedicine.medical_specialtyCOPDEjection fractionbusiness.industryDiastoleCritical Care and Intensive Care Medicinemedicine.diseasePulmonary function testingInternal medicineHeart failureCardiologyMedicineCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionProspective cohort study

description

Background COPD is an established predictor of clinical outcome in patients with chronic heart failure (HF). However, little evidence is available about the predictive value of FEV1 in chronic HF. Research Question Is pulmonary function related to the progression of chronic HF? Study Design and Methods The MyoVasc study ( ClinicalTrials.gov Identifier: NCT04064450) is a prospective cohort study of HF. Information on pulmonary and cardiac functional and structural status was obtained by body plethysmography and echocardiography. The primary study end point was worsening of HF. Results Overall 2,998 participants (age range, 35-84 years) with available FEV1 data were eligible for analysis. Linear multivariate regression analysis revealed an independent relationship of FEV1 (per –1 SD) with deteriorated systolic and diastolic left ventricle (LV) function as well as LV hypertrophy under adjustment of age, sex, height, cardiovascular risk factors (CVRFs), and clinical profile (LV ejection fraction: β-estimate, –1.63% [95% CI, –2.00% to –1.26%]; E/E′ ratio: β-estimate, 0.82 [95% CI, 0.64-0.99]; and LV mass/height2.7: β-estimate, 1.58 [95% CI, 1.07-2.10]; P  Interpretation FEV1 represents a strong candidate to improve future risk stratification and prevention strategies in individuals with chronic, stable HF. Trial Registry ClinicalTrials.gov; No.: NCT04064450; URL: www.clinicaltrials.gov

yearjournalcountryeditionlanguage
2022-01-01Chest
https://doi.org/10.1016/j.chest.2021.07.2176